Évaluation de la toxicité du kétoprofène chez le dragon barbu (Pogona vitticeps)

La cyclooxygénase (COX) 1 augmente significativement dans la peau inflammée des Ophidiens et dans les muscles inflammés des Chéloniens. Les inhibiteurs non sélectifs de la COX-1 et de la COX-2, comme le kétoprofène, pourraient donc réduire l’inflammation plus efficacement chez les reptiles que les inhibiteurs préférentiels de la COX-2. L’objectif de cette étude était d’évaluer les effets adverses potentiels du kétoprofène chez le dragon barbu (Pogona vitticeps). Treize dragons barbus ont été répartis aléatoirement dans trois groupes lors d’une étude prospective, randomisée, contrôlée et en aveugle. Ils ont reçu une administration intramusculaire quotidienne d’un traitement durant 14 jours. Le groupe 1 (n = 5) a reçu de la saline, le groupe 2 (n = 4) a reçu 2 mg/kg de kétoprofène (dilué 1:10 avec de la saline) et le groupe 3 (n = 4) a reçu 20 mg/kg de kétoprofène (non dilué). Des paramètres biochimiques, des tests de sang occulte fécal et le temps de coagulation sanguine ont été évalués avant et après les deux semaines de traitements. Une évaluation histopathologique des reins, du système digestif, du foie et des muscles a été effectuée. Cliniquement, une réaction aux sites d’injections a été détectée dans le groupe 3. Il n’y avait pas de différences dans les valeurs biochimiques et les temps de coagulation avant et après les traitements, ni entre les groupes. Aucune lésion n’a été détectée à l’évaluation histologique des reins, du foie et du tractus gastro-intestinal. Des lésions histopathologiques de nécrose musculaire aux sites d’injections ont été notées dans tous les groupes et elles étaient statistiquement plus sévères dans le groupe 3 que dans le groupe 1. En conclusion, l’administration intramusculaire quotidienne de 2 mg/kg de kétoprofène dilué durant 14 jours n’a pas causé d’effets adverses chez ce petit nombre de dragons barbus, tandis que de la nécrose musculaire sévère a été détectée suite à l’administration de 20 mg/kg de kétoprofène non dilué.Cyclooxygenase (COX) 1 has been shown to increase significantly in inflamed ophidian skin and chelonian muscles. Non-selective COX-1 and COX-2 inhibitors, such as ketoprofen, could therefore reduce inflammation more effectively than preferential COX-2 inhibitors in reptiles. The objective of this study was to evaluate potential adverse effects of ketoprofen in bearded dragons (Pogona vitticeps). Thirteen adult bearded dragons were divided into three groups receiving daily intramuscular injections for 14 days in a prospective randomized controlled blinded study design. Group 1 (n = 5) received saline, group 2 (n = 4) received ketoprofen at 2 mg/kg (diluted 1:10 with saline) and group 3 (n = 4) received ketoprofen at 20 mg/kg (undiluted). Biochemical values, fecal occult blood tests and blood clotting time were assessed before and after the two- week treatment. Renal, digestive, hepatic and muscular histopathology was evaluated. Clinically, injection site reactions were noted in group 3 only. No other clinical adverse effects were detected. No changes were detected in plasma biochemical values and clotting times before and after treatments, nor between control and treatment groups. No lesion associated with ketoprofen toxicity was detected on histologic examination of the kidney, liver and gastrointestinal tract. Histopathological lesions of muscular necrosis at the injection sites were noted in all groups and were statistically more severe in group 3 compared to group 1. In conclusion, daily intramuscular administration of diluted ketoprofen at 2 mg/kg for 14 days did not cause adverse effects in a small number of bearded dragons, while severe muscular necrosis was detected following administration of undiluted ketoprofen at 20 mg/kg

Evaluation of the safety of multiple intramuscular doses of ketoprofen in bearded dragons (Pogona vitticeps)

Cyclooxygenase (COX) 1 has been shown to increase significantly in inflamed ophidian skin and chelonian muscles. Nonselective COX-1 and COX-2 inhibitors, such as ketoprofen, could therefore reduce inflammation more effectively than preferential COX-2 inhibitors in reptiles. The objective of this study was to evaluate potential adverse effects of ketoprofen in bearded dragons (Pogona vitticeps). Thirteen adult bearded dragons were divided into three groups receiving daily intramuscular injections for 14 days in a blinded randomized study design. Group 1 (n = 5) received saline, Group 2 (n = 4) received ketoprofen at 2 mg/kg (diluted 1:10 with saline) and Group 3 (n = 4) received ketoprofen at 20 mg/kg (undiluted). Biochemical values, fecal occult blood (FOB) tests, and blood clotting time were assessed before and after the 2-wk treatment. Renal, digestive, hepatic, and muscular histopathology was evaluated. Clinically, injection-site reactions were noted in Group 3 only (n = 1/4). No other clinical adverse effects were detected. No changes were detected in plasma biochemical values and clotting times before and after treatments, nor were changes detected between control and treatment groups. No lesion associated with ketoprofen toxicity was detected on histologic examination of the kidney, liver, and gastrointestinal tract. Lesions of muscular necrosis at the injection sites were of higher magnitude in Group 3 compared to Group 1. In conclusion, daily intramuscular administration of diluted ketoprofen at 2 mg/kg for 14 days did not cause adverse effects in a small number of bearded dragons, whereas severe muscular necrosis was detected at 20 mg/kg